The Clinical Features of Combined Central and Peripheral Demyelination
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 主要终点
- Laboratory findings of nodal/paranodal antibodies in blood of patients with CCPD
研究概览
简要总结
The investigators conduct this study to clarify the clinical features and to evaluate the prevalence of anti-nodal/paranodal antibodies of patients with combined central and peripheral demyelination (CCPD) .
详细描述
The investigators will review the clinical manifestation, laboratory test results, electrophysiological examination and neuroimaging findings of patients with CCPD. And we will detect antibodies to aquaporin 4(AQP4), myelin oligodendrocyte glycoprotein (MOG), neurofascin-155 (Nfasc155), neurofascin-186 (Nfasc186), and myelin-associated glycoprotein (MAG) in patients with CCPD.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •T2 high-signal intensity lesions in the brain or spinal cord on MRI, or visual-evoked potentials(VEPs) abnormalities.
- •conduction delay, conduction block, temporal dispersion or F-wave abnormalities, suggesting peripheral demyelinating neuropathy regarding nerve conduction studies (NCS).
排除标准
- •infectious diseases(e.g., human T lymphocyte trophic virus type1-associated myelopathy, syphilis, neuroborreliosis, HIV infection or progressive multifocal leukoencephalopathy)
- •pre-existing inflammatory diseases (e.g., sarcoidosis, Behçet's disease, Sjögren's syndrome, vasculitis or other collagen diseases)
- •mitochondrial disease
- •metabolic/toxic diseases (e.g., vitamin deficiency, amyloidosis, chronic alcoholism, diabetes mellitus or subacute myelo-opticoneuropathy due to clioquinol intoxication
- •cervical spondylotic myelopathy
- •syringomyelia
- •spinocerebellar degeneration
- •multiple myeloma, other tumors
- •inherited diseases (e.g., leucodystrophies)
- •cerebrovascular disease
- •non-specific lesions on T2-weighted MRI (e.g., leucoaraiosis).
结局指标
主要结局
Laboratory findings of nodal/paranodal antibodies in blood of patients with CCPD
时间窗: Day 1 post-gathering information of patients in hospital medical record system
These antibody including anti-neurofascin 155(NF155) et.al.
次要结局
- Demographic characteristics(Day 1 post-gathering information of patients in hospital medical record system)
- Neurological symptoms and signs(Day 1 post-gathering information of patients in hospital medical record system)
- Neuroimaging and VEPs findings(Day 1 post-gathering information of patients in hospital medical record system)
- Laboratory findings of blood and cerebrospinal fluid(Day 1 post-gathering information of patients in hospital medical record system)
- Nerve conduction study findings(Day 1 post-gathering information of patients in hospital medical record system)
研究者
haojunwei
Princple investigation
Xuanwu Hospital, Beijing